Tourmaline Bio price target lowered to $15 from $18 at Truist

Truist analyst Srikripa Devarakonda lowered the firm’s price target on Tourmaline Bio to $15 from $18 but keeps a Buy rating on the shares. The firm is updating its model after the company’s Q2 results but also notes that a “catalyst-rich period” for Tourmaline, offering potential for significant upside, is approaching, the analyst tells investors in a research note.